- Home
- AIRI vs CANF Comparison
AIRI vs CANF Comparison
Compare AIRI & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- CANF
- Stock Information
- Founded
- AIRI 1979
- CANF 1994
- Country
- AIRI United States
- CANF Israel
- Employees
- AIRI N/A
- CANF N/A
- Industry
- AIRI Military/Government/Technical
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- AIRI Industrials
- CANF Health Care
- Exchange
- AIRI Nasdaq
- CANF Nasdaq
- Market Cap
- AIRI 13.1M
- CANF 14.8M
- IPO Year
- AIRI N/A
- CANF N/A
- Fundamental
- Price
- AIRI $3.20
- CANF $1.04
- Analyst Decision
- AIRI
- CANF Strong Buy
- Analyst Count
- AIRI 0
- CANF 2
- Target Price
- AIRI N/A
- CANF $14.00
- AVG Volume (30 Days)
- AIRI 11.0K
- CANF 172.6K
- Earning Date
- AIRI 05-15-2025
- CANF 05-27-2025
- Dividend Yield
- AIRI N/A
- CANF N/A
- EPS Growth
- AIRI N/A
- CANF N/A
- EPS
- AIRI N/A
- CANF N/A
- Revenue
- AIRI $55,108,000.00
- CANF $674,000.00
- Revenue This Year
- AIRI $5.59
- CANF $461.72
- Revenue Next Year
- AIRI $5.00
- CANF N/A
- P/E Ratio
- AIRI N/A
- CANF N/A
- Revenue Growth
- AIRI 6.97
- CANF N/A
- 52 Week Low
- AIRI $3.00
- CANF $1.02
- 52 Week High
- AIRI $9.44
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- AIRI 41.31
- CANF 37.30
- Support Level
- AIRI $3.39
- CANF $0.98
- Resistance Level
- AIRI $3.88
- CANF $1.14
- Average True Range (ATR)
- AIRI 0.21
- CANF 0.06
- MACD
- AIRI -0.00
- CANF 0.01
- Stochastic Oscillator
- AIRI 2.70
- CANF 32.59
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).